An Open-label, Non-randomised, Multicentre Study to Allow Continued Access to and Assess the Safety and Tolerability of AZD1775 for Patients Enrolled in AZD1775 Clinical Pharmacology Studies
Phase of Trial: Phase I
Latest Information Update: 19 Dec 2018
At a glance
- Drugs Adavosertib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors AstraZeneca
- 11 Dec 2018 Planned End Date changed from 16 Aug 2019 to 11 Aug 2020.
- 11 Dec 2018 Planned primary completion date changed from 16 Aug 2019 to 11 Aug 2020.
- 10 May 2018 Planned number of patients changed from 42 to 52.